



openheart Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block

Douglas Cannie ^{1,2}, Kush Patel,^{1,2} Alexandros Protonotarios,^{1,2} Imogen Heenan,¹ Athanasios Bakalakos ^{1,2}, Petros Syrris,¹ Leon Menezes,^{1,2} Perry M Elliott^{1,2}

To cite: Cannie D, Patel K, Protonotarios A, *et al.* Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block. *Open Heart* 2024;**11**:e002606. doi:10.1136/openhrt-2024-002606

Received 7 January 2024
Accepted 12 March 2024

ABSTRACT

Objective Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiac disorder caused by deposition of wild type or mutated transthyretin. As ATTR-CM is associated with conduction disease, we sought to determine its prevalence in patients with idiopathic high-degree atrioventricular (AV) block requiring permanent pacemaker (PPM) implantation.

Methods Consecutive patients aged 70–85 years undergoing PPM implantation for idiopathic high-degree AV block between November 2019 and November 2021 were offered a 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan. Demographics, comorbidities, electrocardiographic and imaging data from the time of device implantation were retrospectively collected.

Results 39 patients (79.5% male, mean (SD) age at device implantation 76.2 (2.9) years) had a DPD scan. 3/39 (7.7%, all male) had a result consistent with ATTR-CM (Perugini grade 2 or 3). Mean (SD) maximum wall thickness of those with a positive DPD scan was 19.0 mm (3.6 mm) vs 11.4 mm (2.7 mm) in those with a negative scan ($p=0.06$). All patients diagnosed with ATTR-CM had spinal canal stenosis and two had carpal tunnel syndrome.

Conclusions ATTR-CM should be considered in older patients requiring permanent pacing for high-degree AV block, particularly in the presence of left ventricular hypertrophy, carpal tunnel syndrome or spinal canal stenosis.

INTRODUCTION

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease of the myocardium caused by deposition of wild-type or mutated transthyretin amyloid fibrils in the extracellular space. Left untreated, the median survival for patients with ATTR-CM_{wt} is 3.6 years¹ and 2.6 years for those with ATTR-CM_m caused by the most common genetic variant, p.Val142Ile.² Treatment with tafamidis, a novel non-NSAID (non-steroidal anti-inflammatory drug) benzoxazole derivative that selectively binds the thyroxine binding sites of the transthyretin tetramer inhibiting its dissociation,^{3–7} has been shown to reduce

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ There is a high prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with common presentations of cardiac disease.

WHAT THIS STUDY ADDS

⇒ There is an 8% prevalence of ATTR-CM in older patients requiring a pacemaker for high-degree atrioventricular (AV) block. Patients with ATTR-CM exhibited known red flag features of the disease such as left ventricular hypertrophy, carpal tunnel syndrome or spinal canal stenosis.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ A high-degree of clinical suspicion should be maintained for a diagnosis of ATTR-CM in older patients requiring a pacemaker for high-degree AV block, particularly in the presence of known red flag features of the disease.

the risk of death and cardiovascular-related hospitalisations and to slow the decline in functional capacity and quality of life.⁸ Therefore, early diagnosis of ATTR-CM is essential to identify patients who would benefit from disease-modifying therapy.

ATTR-CM is characterised by increased left ventricular (LV) wall thickness, impairment of left ventricular (LV) systolic and diastolic function and conduction abnormalities necessitating permanent pacemaker (PPM) implantation.⁹ Recent studies have shown a high prevalence of ATTR-CM in patients with common presentations of cardiac disease. For example, ATTR-CM was found in 15% of patients with heart failure with preserved ejection fraction and 13% of individuals with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).^{10–13} The aim of this study was to determine the prevalence of ATTR-CM in older patients undergoing PPM implantation for high-grade atrioventricular (AV) block.¹⁴



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

¹University College London, London, UK

²St Bartholomew's Hospital, London, UK

Correspondence to

Dr Douglas Cannie; d.cannie@ucl.ac.uk

Table 1 Baseline features of patients undergoing permanent pacemaker implantation for high degree atrioventricular block, stratified by outcome of nuclear scintigraphy

	Overall	Negative DPD	Positive DPD	P value
n	39	36	3	
Sex, n (%)	31 (79.5)	28 (77.8)	3 (100.0)	1
Age at PPM implant, mean (SD)	76.2 (2.9)	75.9 (2.6)	80.5 (3.7)	0.2
White ethnicity, n (%)	33 (84.6)	30 (83.3)	3 (100.0)	1
LV internal diameter (mm), mean (SD)	49.6 (7.6)	49.9 (7.4)	46.7 (10.4)	0.6
Left atrial diameter (mm), mean (SD)	40.0 (6.1)	39.8 (6.2)	41.3 (5.9)	0.7
LV ejection fraction (%), median(Q1, Q3)	57.5 (52, 61.0)	57.5 (54, 60.5)	39.0 (31, 51)	0.2
Maximum LV wall thickness (mm), mean (SD)	12.1 (3.4)	11.4 (2.6)	19.0 (3.6)	0.06
Coronary artery disease, n (%)	3 (7.7)	2 (5.6)	1 (33.3)	0.2
Severe valve disease, n (%)	1 (2.6)	1 (2.8)	0	1
Diabetes mellitus, n (%)	10 (25.6)	9 (25.0)	1 (33.3)	1
Hypercholesterolaemia, n (%)	25 (64.1)	23 (63.9)	2 (66.7)	1
Hypertension, n (%)	21 (53.8)	20 (55.6)	1 (33.3)	0.6
Ever smoked cigarettes, n (%)	23 (59.0)	22 (61.1)	1 (33.3)	0.6
Stroke, n (%)	1 (2.6)	1 (2.8)	0	1
Heart failure, n (%)	4 (10.3)	3 (8.3)	1 (33.3)	0.3
Previous atrial fibrillation, n (%)	10 (25.6)	10 (27.8)	0	0.6
Previous NSVT, n (%)	1 (2.6)	0	1 (33.3)	0.08
Third degree AV block, n (%)	24 (61.5)	22 (61.1)	2 (66.7)	1
Carpal tunnel syndrome, n (%)	4 (10.3)	2 (5.6)	2 (66.7)	0.02
Spinal canal stenosis, n (%)	3 (7.7)	0	3 (100.0)	<0.001

Negative DPD scans were those with Perugini grade 0 and positive scans were Perugini grade 2 or 3.
 All patients who did not have 3rd degree AV block had fixed 2:1 AV block.
 AV, atrioventricular; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; LV, left ventricular; NSVT, non-sustained ventricular tachycardia; PPM, permanent pacemaker.

METHODS

This was a single-centre, prospective study with participating patients providing written informed consent.¹⁵ Patients or the public were not involved in the design, conduct or reporting plans of the study.

Device implantation records at Barts Heart Centre were used to identify patients aged 70–85 years who had required PPM implantation for high-degree AV block between November 2019 and November 2021. Patients were excluded when high-degree AV block was attributable to myocardial infarction, recent cardiothoracic surgery or TAVI. Patients were also excluded when comorbidities precluded travel for nuclear scintigraphy or where patients did not have capacity to consent.

Consenting patients underwent nuclear scintigraphy with 99mTechnetium (Tc)-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) at Barts Heart Centre with results reported by local specialist radiologists. Demographics, comorbidities, rhythm and imaging data were retrospectively collected. A positive DPD scan was defined as a Perugini grade 2 or 3.¹⁶ Where a

Table 2 Features of patients with Perugini grade 2 or 3 on DPD scan

	Patient 1	Patient 2	Patient 3
Sex, n (%)	Male	Male	Male
Comorbidities	Hypothyroidism	MI, T2DM, prostate cancer	Hypertension
Age at device implantation (years)	84.8	78.6	78.1
LV internal diameter (mm)	35	55	50
Left atrial diameter (mm)	37	48	39
LV ejection fraction (%)	62.5	22.5	39
Maximum LV wall thickness (mm)	20	15	22
Previous arrhythmia	NSVT	Nil	Nil
NTproBNP (ng/L)	983	3462	626
Perugini grade	2	2	3
Degree of heart block	Fixed 2:1	Third degree	Third degree
Light chain amyloidosis screen	Negative	Negative	Negative
Genotype	Wild-type	Wild-type	Wild-type
Carpal tunnel syndrome	Yes	No	Yes
Spinal canal stenosis	Yes	Yes	Yes
Biceps tendon rupture	No	No	No

DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; LV, left ventricular; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NTproBNP, N-terminal pro-B-type natriuretic peptide.; T2DM, type 2 diabetes mellitus.

positive result was returned, patients were referred into a specialist cardiomyopathy service for further investigation including exclusion of light chain (AL) amyloidosis (with serum and urine electrophoresis and serum free AL assays) and *TTR* gene sequencing.

All data were anonymised and statistical analyses performed using the Python programming language (V.3.8, Python Software Foundation).¹⁷ Continuous variables were tested for normality of distribution by visual inspection of histograms and statistical normality tests (Shapiro-Wilk). Normally distributed variables are expressed as mean±SD and non-normally distributed variables as median (25th, 75th percentiles). Categorical variables are reported as counts and percentages, as appropriate. The *TableOne* library was used for the construction of summary statistics tables and for all statistical comparisons.¹⁸

RESULTS

355 patients aged 70–85 years requiring PPM implantation for high-degree AV block within the recruitment period were identified. Following case note review, 162 patients were approached to participate in the study. 39 patients (79.5% male with mean (SD) age at device implantation of 76.2 (2.9) years) had a DPD scan. Remaining patients declined to participate, with most citing frailty in combination with anxiety concerning COVID-19. Three of 39 patients undergoing a DPD scan (7.7%, all male) had a result consistent with a diagnosis of ATTR-CM. All remaining scans were Perugini grade




Figure 1 Investigations for a male in his ninth decade requiring ICD implantation for 2:1 AV block and ventricular arrhythmia. Perugini grade 3 uptake on DPD scan (top left) consistent with a diagnosis of transthyretin amyloidosis cardiomyopathy. ECG showing low voltage QRS complexes in limb leads and first-degree heart block (top right). Traces from Holter monitoring showing 2:1 fixed AV block and non-sustained ventricular tachycardia (bottom left). Echocardiography showing concentric left ventricular hypertrophy and near complete cavity obliteration in systole (bottom right). AV, atrioventricular; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; ICD, implantable cardioverter defibrillator.

0. **Table 1** shows baseline characteristics stratified by the result of DPD scan.

Mean (SD) maximum LV wall thickness of patients with a positive DPD scan was 19mm (3.6mm) vs 11.4mm (2.7mm) in those with a negative scan ($p=0.06$). All three patients who returned a positive DPD result had a history of spinal canal stenosis and two had carpal tunnel syndrome. All three had a wild-type genotype. Clinical features of patients with a positive DPD scan are shown in **table 2** and **figure 1**.

DISCUSSION

Previously considered a rare disease, ATTR-CM has been shown to be prevalent in a range of cardiac disease cohorts.¹⁹ Diagnosis is aided by certain ‘red flag’ features including a history of carpal tunnel syndrome or spinal canal stenosis, low limb lead voltages on ECG and echocardiographic features such as concentric LV hypertrophy and reduced global longitudinal ventricular strain with apical sparing.^{20,21}

Conduction disease is a well-recognised feature of ATTR-CM, with just under 1 in 10 newly diagnosed patients requiring PPM implantation.⁹ Conversely, the prevalence of ATTR-CM in patients requiring a PPM is less certain, with only a single study to date showing a prevalence of less than 2% in patients over 60 years of age requiring pacing.²² While this study’s inclusion criteria allowed recruitment of younger

patients, the mean age was higher than that seen in our study. There was, however, a lower proportion of males (56% vs 78%) which may explain the higher prevalence of ATTR-CM in our cohort. Of note, patients with a positive DPD scan all had LV hypertrophy and a prior history of carpal tunnel syndrome or spinal canal stenosis, illustrating the importance of such diagnostic red flags in directing the investigation of high-grade AV block. In comparison, the prevalence of diagnostic red flags was very low in patients returning a negative DPD scan.

Tafamidis, a TTR-stabilising agent, has received a class 1B recommendation in the European Society of Cardiology heart failure guidelines for use in ATTR-CM patients with NYHA class I or II symptoms.²³ Clinical trials examining other TTR-stabilising agents, gene silencers and gene editing technologies are showing promise.^{24,25} This prospective study highlights the importance of maintaining a high-degree of suspicion for ATTR-CM in older patients requiring a PPM so that they too can be offered disease-modifying therapy.

To maximise the potential of new therapies, early diagnosis of ATTR-CM is key. This is particularly the case in the presence of high-degree AV block which appears to herald a poorer prognosis in patients with ATTR-CM. A recent study found that the presence of a PPM at baseline assessment was associated with a significantly higher risk of heart failure admissions and a trend towards a higher rate of mortality.²⁶

In a second study, death from any cause occurred in 83% of ATTR-CM patients who developed high-degree AV block during follow-up vs 29% without conduction disease. High-degree AV block was significantly associated with all-cause mortality on univariable analysis but did not reach statistical significance in a multivariable model.⁹

LIMITATIONS

The study is limited by the small cohort size. The low recruitment rate can be attributed to the frailty of the target population in combination with the occurrence of the COVID-19 pandemic during the study period.

CONCLUSION

Eight per cent of individuals between 70 and 85 years of age undergoing PPM implantation for high-degree AV block have ATTR-CM.

Twitter Douglas Cannie @dougcanie and Athanasios Bakalakos @ath_bakalagos

Acknowledgements The authors are grateful to the patients and their families whose contributions have made this work possible. This study was supported by Pfizer, the British Heart Foundation and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The abstract of this work was presented at the British Cardiovascular Society Conference (2023; https://heart.bmj.com/content/109/Suppl_3/A11).

Contributors DC: conceptualisation and design of the study, data collection and analysis, drafting and revising the manuscript and acquisition of funding and resources. KP conceptualisation and design of the study and data collection and analysis. AP: conceptualisation and design of the study and data collection and analysis. IH: data collection and analysis. AB: conceptualisation and design of the study and data collection and analysis. PS: conceptualisation and design of the study, data collection and analysis and acquisition of funding and resources. LM: conceptualisation and design of the study, data collection and analysis and acquisition of funding and resources. PME: conceptualisation and design of the study, data collection and analysis, drafting and revising the manuscript, acquisition of funding and resources, project supervision and guarantor.

Funding Financial support was provided as a Research Grant from Pfizer (award number W1246510) and a British Heart Foundation clinical research training fellowship to DC (FS/CRTF/20/24022).

Competing interests PME: consultancies and speaker fees Pfizer.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and ethical approval was received from local research ethics committees (20/LO/0315 and 19/WS/0100). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Douglas Cannie <http://orcid.org/0000-0001-6298-922X>

Athanasios Bakalakos <http://orcid.org/0009-0006-6356-2205>

REFERENCES

- Lane T, Fontana M, Martinez-Naharro A, *et al*. Natural history, quality of life, and outcome in cardiac Transthyretin Amyloidosis. *Circulation* 2019;140:16–26.
- Grogan M, Scott CG, Kyle RA, *et al*. Natural history of wild-type Transthyretin cardiac Amyloidosis and risk stratification using a novel staging system. *J Am Coll Cardiol* 2016;68:1014–20.
- Johnson SM, Connelly S, Fearn C, *et al*. The Transthyretin Amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. *J Mol Biol* 2012;421:185–203.
- Bulawa CE, Connelly S, DeVit M, *et al*. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proc Natl Acad Sci USA* 2012;109:9629–34.
- Razavi H, Palaninathan SK, Powers ET, *et al*. Benzoxazoles as Transthyretin Amyloid Fibril inhibitors: synthesis, evaluation, and mechanism of action. *Angew Chem Int Ed Engl* 2003;42:2758–61.
- Rappley I, Monteiro C, Novais M, *et al*. Quantification of Transthyretin kinetic stability in human plasma using subunit exchange. *Biochemistry* 2014;53:1993–2006.
- Cho Y, Baranczak A, Helmke S, *et al*. Personalized medicine approach for optimizing the dose of Tafamidis to potentially ameliorate wild-type Transthyretin Amyloidosis (cardiomyopathy). *Amyloid* 2015;22:175–80.
- Maurer MS, Schwartz JH, Gundapaneni B, *et al*. Tafamidis treatment for patients with Transthyretin Amyloid cardiomyopathy. *N Engl J Med* 2018;379:1007–16.
- Donnellan E, Wazni OM, Saliba WJ, *et al*. Prevalence, incidence, and impact on mortality of conduction system disease in Transthyretin cardiac Amyloidosis. *Am J Cardiol* 2020;128:140–6.
- González-López E, Gallego-Delgado M, Guzzo-Merello G, *et al*. Wild-type Transthyretin Amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J* 2015;36:2585–94.
- Hahn VS, Yanek LR, Vaishnav J, *et al*. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac Amyloidosis. *JACC Heart Fail* 2020;8:712–24.
- Lindmark K, Pilebro B, Sundström T, *et al*. Prevalence of wild type Transthyretin cardiac Amyloidosis in a heart failure clinic. *ESC Heart Fail* 2021;8:745–9.
- Scully PR, Treibel TA, Fontana M, *et al*. 1 A multi-centre study of cardiac Amyloidosis in Tavi patients. British Cardiovascular Imaging Meeting 2018, 2–4th May 2018, Edinburgh; May 2018
- Cannie D, Patel K, Menezes L, *et al*. 9 Prevalence of transthyretin cardiac amyloidosis in patients with high degree AV block. British Cardiovascular Society Annual Conference, 'Future-proofing Cardiology for the next 10 years', 5–7 June 2023; June 2023:A11–2
- World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191–4.
- Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, *et al*. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. *Int J Cardiol* 2018;270:192–6.
- van Rossum G. *Python 3 Reference Manual*. Scotts Valley, CA: CreateSpace, 2009.
- Pollard TJ, Johnson AEW, Raffa JD, *et al*. Tableone: an open source python package for producing summary statistics for research papers. *JAMIA Open* 2018;1:26–31.
- Aimo A, Merlo M, Porcari A, *et al*. Redefining the epidemiology of cardiac Amyloidosis. A systematic review and meta-analysis of screening studies. *Eur J Heart Fail* 2022;24:2342–51.
- Maurer MS, Bokhari S, Damy T, *et al*. Expert consensus recommendations for the suspicion and diagnosis of Transthyretin cardiac Amyloidosis. *Circ Heart Fail* 2019;12:e006075.
- Merlo M, Pagura L, Porcari A, *et al*. Unmasking the prevalence of Amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey. *Eur J Heart Fail* 2022;24:1377–86.
- López-Sainz Á, de Haro-Del Moral FJ, Dominguez F, *et al*. Prevalence of cardiac Amyloidosis among elderly patients with systolic heart failure or conduction disorders. *Amyloid* 2019;26:156–63.
- McDonagh TA, Metra M, Adamo M, *et al*. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599–726.
- Tschöpe C, Elsanhoury A. Treatment of Transthyretin Amyloid cardiomyopathy: the current options, the future, and the challenges. *J Clin Med* 2022;11:2148.
- Monda E, Bakalakos A, Rubino M, *et al*. Targeted therapies in pediatric and adult patients with hypertrophic heart disease: from molecular pathophysiology to personalized medicine. *Circ Heart Fail* 2023;16:e010687.
- Ladefoged BT, Dybro A, Dahl Pedersen AL, *et al*. Incidence and predictors of worsening heart failure in patients with wild-type Transthyretin cardiac Amyloidosis. *ESC Heart Fail* 2022;9:2978–87.